Background Allergen immunotherapy (AIT) is the only causal treatment for respiratory
allergy. Long-term real-life effectiveness of AIT remains to be demonstrated beyond the …

Gut microbiota are known to impact multiple organs including the lung. The cross talk
between gut microbes and lungs, termed as the “gut–lung axis,” is vital for immune response …

The current COVID-19 pandemic influences many areas of social life, medical treatments
and the way allergy diagnosis and treatment is performed. Allergen-specific immunotherapy …

The type 2 cytokine-high asthma endotype (T2H) is characterized by IL-13-driven mucus
obstruction of the airways. To further investigate this incompletely understood pathobiology …

Without vaccination, an estimated 1 in 3 individuals will develop herpes zoster (HZ) in their
lifetime. Increased risk of HZ is attributed to impaired cell-mediated immunity, as observed in …

Rationale: Allergic asthma is linked to impaired bronchial epithelial secretion of IFNs, which
may be causally linked to the increased risk of viral exacerbations. We have previously …

Background Allergic asthma is associated with increased risk of respiratory tract infections
and exacerbations. It remains unclear whether this susceptibility is conditioned by seasonal …

Allergen-specific immunotherapy (AIT) is the only causal therapy with a proven long-term
benefit in allergic airway diseases, such as allergic bronchial asthma or allergic …

Background There is limited evidence on the pathways leading to severe asthma and we
are presently unable to effectively predict the progression of the disease. We aimed to …

Introduction Allergen exposure worsens viral‐triggered asthma exacerbations and could
predispose the host to secondary bacterial infections. We have previously demonstrated that …